RenovoRx, Inc.RNXTEarnings & Financial Report
RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapy delivery systems for cancer treatment. Its core assets include proprietary transarterial delivery platforms, with primary operations in the United States, serving unmet medical needs in the oncology care segment.
Revenue
$266.0K
Gross Profit
$213.0K
Operating Profit
$-3.2M
Net Profit
$-2.9M
Gross Margin
80.1%
Operating Margin
-1203.0%
Net Margin
-1094.7%
YoY Growth
N/A
EPS
$-0.08
RenovoRx, Inc. Q3 FY2025 Financial Summary
RenovoRx, Inc. reported revenue of $266.0K for Q3 FY2025, with a net profit of $-2.9M (down 17.8% YoY) (-1094.7% margin). Cost of goods sold was $53.0K, operating expenses totaled $3.4M.
Key Financial Metrics
| Total Revenue | $266.0K |
|---|---|
| Net Profit | $-2.9M |
| Gross Margin | 80.1% |
| Operating Margin | -1203.0% |
| Report Period | Q3 FY2025 |
RenovoRx, Inc. Annual Revenue by Year
RenovoRx, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.1M |
RenovoRx, Inc. Quarterly Revenue & Net Profit History
RenovoRx, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $238.0K | — | $-2.9M | -1235.7% |
| Q3 FY2025 | $266.0K | — | $-2.9M | -1094.7% |
| Q2 FY2025 | $422.0K | — | $-2.9M | -686.0% |
| Q1 FY2025 | $197.0K | — | $-2.4M | -1228.4% |
| Q1 FY2022 | $1.0K | — | $-3.0M | -300300.0% |
Income Statement
| Q1 2022 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Revenue | $1000 | $197000 | $422000 | $266000 | $238000 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2022 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Assets | $13.9M | $16.0M | $13.6M | $11.2M | $8.1M |
| Liabilities | $1.4M | $2.9M | $3.0M | $3.1M | $2.7M |
| Equity | $12.5M | $13.2M | $10.6M | $8.1M | $5.4M |
Cash Flow
| Q1 2022 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Operating CF | $-2.1M | $-3.4M | $-2.3M | $-2.3M | $-3.0M |